[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20140618A1 - Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa - Google Patents

Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa

Info

Publication number
PE20140618A1
PE20140618A1 PE2013002520A PE2013002520A PE20140618A1 PE 20140618 A1 PE20140618 A1 PE 20140618A1 PE 2013002520 A PE2013002520 A PE 2013002520A PE 2013002520 A PE2013002520 A PE 2013002520A PE 20140618 A1 PE20140618 A1 PE 20140618A1
Authority
PE
Peru
Prior art keywords
phenyl
oxo
alkyl
diacilglicerol
aciltransferase
Prior art date
Application number
PE2013002520A
Other languages
English (en)
Inventor
Donghui Qin
Hemant Joshi
Raghuram Tangirala
Siegfried Benjamin Christensen Iv
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140618(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of PE20140618A1 publication Critical patent/PE20140618A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C6), CICLOALQUILO(C3-C7), ARILO, ENTRE OTROS; R2 ES H, ALQUILO(C1-C3), ALCOXI, CN, ENTRE OTROS; R4 ES CH2COOH, COOH, ESTER O AMIDA; R5 ES H, HIDROXILO U OXO; R7 ES H O ALQUILO(C1-C3); X ES C O N; Y ES N O CR3, EN DONDE R3 ES H, ALQUILO(C1-C6), HALOGENO, ENTRE OTROS; m ES DE 0 A 3; n ES 0 O 1. SON COMPUESTOS PREFERIDOS: ACIDO 2-{1-OXO-6-[4-({[4-(TRIFLUOROMETIL)FENIL]CARBAMOIL}AMINO)FENIL]-1,2,3,4-TETRAHIDROISOQUINOLIN-2-IL}ACETICO; ACIDO 2-[6-(4-{[(3-METILFENIL)CARBAMOIL]AMINO}FENIL)-1-OXO-1,2,3,4-TETRAHIDROISOQUINOLIN-2-IL]ACETICO; ACIDO 2-{1-OXO-6-[4-({[4-(TRIFLUOROMETOXI)FENIL]CARBAMOIL}-AMINO)FENIL]-1,2,3,4-TETRAHIDROISOQUINOLIN-2-IL}ACETICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE ACIL COENZIMA A DIACILGLICEROL ACILTRANSFERASA 1 (DGAT-1) SIENDO UTILES EN EL TRATAMIENTO DE OBESIDAD, HIPERLIPOPROTEINEMIA, DISLIPIDEMIA
PE2013002520A 2011-05-20 2012-05-18 Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa PE20140618A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1451DE2011 2011-05-20
US201161495049P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
PE20140618A1 true PE20140618A1 (es) 2014-06-05

Family

ID=47217644

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002520A PE20140618A1 (es) 2011-05-20 2012-05-18 Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa

Country Status (19)

Country Link
US (1) US9242929B2 (es)
EP (1) EP2723332B1 (es)
JP (1) JP5893724B2 (es)
KR (1) KR20140033426A (es)
CN (1) CN103687595B (es)
AU (1) AU2012259042B2 (es)
CA (1) CA2836666A1 (es)
CO (1) CO6811853A2 (es)
CR (1) CR20130603A (es)
DO (1) DOP2013000273A (es)
EA (1) EA023239B1 (es)
ES (1) ES2572261T3 (es)
IL (1) IL229487A0 (es)
MA (1) MA35398B1 (es)
MX (1) MX2013013565A (es)
PE (1) PE20140618A1 (es)
SG (1) SG194976A1 (es)
WO (1) WO2012162127A1 (es)
ZA (1) ZA201308569B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015121380A (ru) * 2012-11-09 2017-01-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы
WO2014081995A1 (en) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
WO2022026380A1 (en) * 2020-07-29 2022-02-03 Board Of Regents, The University Of Texas System Urea inhibitors of micro-rna
CN111747876B (zh) * 2020-08-03 2023-05-26 万华化学集团股份有限公司 一种氧化角黄素制备虾青素的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200606137A (en) 2004-07-02 2006-02-16 Sankyo Co Urea derivatives
JP2006045209A (ja) * 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
CA2605300A1 (en) * 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
CN103086981A (zh) 2006-03-31 2013-05-08 诺瓦提斯公司 新化合物
GB0625654D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
WO2008099221A1 (en) * 2007-02-15 2008-08-21 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
JP2008255024A (ja) * 2007-04-02 2008-10-23 Banyu Pharmaceut Co Ltd ビアリールアミン誘導体
WO2009126861A2 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolopyridine compounds useful as dgat1 inhibitors
EP2471777A4 (en) 2009-08-28 2013-01-02 Daiichi Sankyo Co Ltd NOVEL TETRAHYDROISOQUINOLINE COMPOUNDS
JP2011088889A (ja) * 2009-09-24 2011-05-06 Daiichi Sankyo Co Ltd 新規テトラヒドロイソキノリン誘導体を含有する医薬
CN102781915A (zh) 2009-12-31 2012-11-14 皮拉马尔有限公司 二酰甘油酰基转移酶抑制剂
US8314120B2 (en) * 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors

Also Published As

Publication number Publication date
ZA201308569B (en) 2014-07-30
CR20130603A (es) 2014-09-09
US9242929B2 (en) 2016-01-26
DOP2013000273A (es) 2014-04-15
JP2014525895A (ja) 2014-10-02
EA023239B1 (ru) 2016-05-31
MA35398B1 (fr) 2014-09-01
CN103687595B (zh) 2017-05-24
CO6811853A2 (es) 2013-12-16
ES2572261T3 (es) 2016-05-31
EA201391724A1 (ru) 2014-04-30
JP5893724B2 (ja) 2016-03-23
SG194976A1 (en) 2013-12-30
CA2836666A1 (en) 2012-11-29
EP2723332A1 (en) 2014-04-30
IL229487A0 (en) 2014-01-30
EP2723332B1 (en) 2016-03-02
CN103687595A (zh) 2014-03-26
US20150307445A1 (en) 2015-10-29
WO2012162127A1 (en) 2012-11-29
AU2012259042A1 (en) 2013-04-18
AU2012259042B2 (en) 2015-06-11
MX2013013565A (es) 2014-01-08
EP2723332A4 (en) 2014-10-15
KR20140033426A (ko) 2014-03-18

Similar Documents

Publication Publication Date Title
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20141230A1 (es) Inhibidor de cetp de oxazolidinona biciclico fusionado
PE20141120A1 (es) Compuestos heterociclicos
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20120081A1 (es) Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20140859A1 (es) Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
PE20141974A1 (es) Compuestos de heterociclilo
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20110906A1 (es) Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
PE20141405A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20090815A1 (es) Compuesto de amida
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20090679A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina

Legal Events

Date Code Title Description
FD Application declared void or lapsed